While use of a CliniMACS Prodigy® device was already shown for the generation of CAR-T [21–24] and for the expansion of untransduced NK cells [25], this is the first report on the automated generation of CD33-CAR-NK cells using the CliniMACS Prodigy® platform resulting in a proof-of-concept evaluation in a xenograft AML model in vivo. Here, CD33 is linked to acute myeloid leukemia.